Anti-carcinogenic effects of the phenolic-rich extract from abnormal Savda Munziq in association with its cytotoxicity, apoptosis-inducing properties and telomerase activity in human cervical cancer cells (SiHa)

BMC Complementary and Alternative Medicine

Halmurat Upur²  Nurmuhammat Amat²  Tangnur Ablimit¹  Guzalnur Abdixkur¹  Li Hua¹  Fatima Mijit¹  Guzalnur Abliz¹ 

[1] Fifth Department of Gynecology, Affiliated Tumor Hospital, Xinjiang Medical University, Urumqi 830011, Xinjiang, China;Traditional Uighur Medicine Institute, Xinjiang Medical University, 393 Medical University Road, Urumqi 830011, Xinjiang, PR China

关键词: Telomerase;    Apoptosis;    SiHa cells;    Human cervical cancer;    Phenolic rich extracts of ASMq;   

Others  :  1127109
DOI  :  10.1186/s12906-015-0530-x

 received in 2014-07-10, accepted in 2015-01-16,  发布年份 2015

【 摘 要 】

Background

Abnormal Savda Munziq (ASMq) is a herbal preparation used in Traditional Uighur Medicine for the treatment cancer. The polyphenol is main compounds contained in ASMq preparation responsible for anticancer effect of ASMq.

Methods

In this study,Real-time quantitative Polymerase Chain Reaction (RT-PCR) assay, MTT assay and flow cytometry were used to investigate the effect of polyphenol of ASMq on cell viability and the potential of the phenolic rich extracts of ASMq to induce apoptosis in human cervical cancer cells SiHa and its effects on telomerase activity were investigated. Cellular morphological change was observed by phase contrast microscopy. The MTT cell viability data revealed that treatment with phenolic rich extracts at 75 ~ 175 μg/ml significantly inhibited the viability and proliferation of cells, and these effects occurred in a concentration-dependent manner and time dependent manner (P < 0.01).

Results

The phenolic rich extracts can induce apoptosis of SiHa cells, can increase the apoptosis rate in a concentration-dependent manner and time dependent manner (P < 0.01). Growth inhibition and apoptosis induction by phenolic rich extracts treatment on SiHa cells was associated with down-regulation of anti-apoptotic Bcl-2 expression and telomerase (P < 0.05) and Survivin expression. In addition, phenolic rich extracts exerted a dose-dependent induction of FHIT expression.

Conclusion

These results suggest that phenolic rich extracts may have anti-tumor effects in human cervical cancer through cytotoxicity, apoptosis-inducing properties and telomerase activity.

【 授权许可】

   
2015 Abliz et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Schoell WM, Janicek MF, Mirhashmi R: Epidemiology and biology of cervical cancer. Semin Surg Oncol 1999, 16:203-11.
• [2]Parkin DM, Bray F, Ferlay J, Pisani P: Estimating the world cancer burden: globocan. Int J Cancer 2001, 94:153-6.
• [3]Ferlay J, Bray F, Pisani P, Parkin DM: Globocan 2002: cancer incidence, mortality and prevalence worldwide. IARC Press, Lyon; 2004.
• [4]Holmes K, Egan B, Swan N, Morain CO: Genetic mechanisms and aberrant gene expression during the development of gastric intestinal metaplasia and adenocarcinoma. Curr Genomics 2007, 8:379-97.
• [5]McDonald ER, El-Deiry WS: Cell cycle control as a basis for cancer drug development. Int J Oncol 2000, 16:871-86.
• [6]Schultz DR, Harrington WJJ: Apoptosis: programmed cell death at a molecular level. Semin Arthritis Rheum 2003, 32:345-69.
• [7]Decaudin D, Marzo I, Brenner C, Kroemer G: Mitochondria in chemotherapy-induced apoptosis: a prospective novel target of cancer therapy. Inter J Oncol 1998, 12:141-52.
• [8]Adams JM, Cory S: Life-or-death decisions by the Bcl-2 protein family. Trends in Biochem Sci 2001, 26:61-6.
• [9]Deveraux QL, Reed JC: IAP family proteins–suppressors of apoptosis. Genes Dev 1999, 13:239-52.
• [10]Oulton R, Harrington L: Telomeres, telomerase, and cancer: life on the edge of genomic stability. Current Opin Oncol 2000, 12:74-81.
• [11]Hahn WC, Meyerson M: Telomerase activation, cellular immortalization and cancer. Ann Med 2001, 33:123-9.
• [12]Ramachandran C, Fonseca HB, Jhabvala P, Escalon EA, Melnick SJ: Curcumin inhibits telomerase activity through human telomerase reverse transcriptase in MCF-7 breast cancer cell line. Cancer Lett 2002, 184:1-6.
• [13]Ramirez R, Carracedo J, Jimenez R, Canela A, Herrera E, Aljama P, et al.: Massive telomere loss is an early event of DNA damaged-induced apoptosis. J Biol Chem 2003, 278:836-42.
• [14]Mainardi T, Kapoor S, Bielory L: Complementary and alternative medicine: herbs, phytochemicals and vitamins and their immunologic effects. J Allergy and Clin Immunol 2009, 123:283-94.
• [15]Balunas MJ, Kinghorn AD: Drug discovery from medicinal plants. Life Sci 2005, 78:431-41.
• [16]da Rocha AB, Lopes RM, Schwartsmann G: Natural products in anticancer therapy. Curr Opin Pharmacol 2001, 1:364-9.
• [17]Gu R, Wang Y, Long B, Kennelly E, Wu S, Liu B, et al.: Prospecting for bioactive constituents from traditional medicinal plants through ethnobotanical approaches. Biol Pharm Bull 2014, 37:903-15.
• [18]Yang CS, Landaa JM, Huang MT, Newmark HL: Inhibition of carcinogenesis by dietary polyphenolic compound. Annu Rev Nutr 2001, 21:381-406.
• [19]Yang CS, Lambert JD: Shengmin Sang Antioxidative and anti-carcinogenic activities of tea polyphenols. Arch Toxicol 2009, 83:11-21.
• [20]Ullmannova V, Popescu NC: Inhibition of cell proliferation, induction of apoptosis, reactivation of DLC1, and modulation of other gene expression by dietary flavone in breast cancer cell lines. Cancer Detec Preven 2007, 31:110-8.
• [21]Wenzel U, Kuntz S, Brendel MD, Daniel H: Dietary flavone is a potent apoptosis inducer in human colon carcinoma cells. Cancer Res 2000, 60:3823-31.
• [22]Jeong SH, Jo WS, Song S, Suh H, Seol SY, Leem SH, et al.: A novel resveratrol derivative, HS1793, overcomes the resistance conferred by Bcl-2 in human leukemic U937 cells. Biochem Pharmacol 2009, 77:1337-47.
• [23]Upur H, Yusup A, Umar A, Moore N: Uighur traditional medicine syndrome of abnormal Savda in men is associated with oxidative stress, which can be improved by Munziq and Mushil of Abnormal Savda. Therapie 2004, 59:483-4.
• [24]Upur H, Yusup A, Baudrimont I, Umar A, Berke B, Yimit D. Inhibition of cell growth and cellular protein, DNA and RNA synthesis in human hepatoma (HepG2) cells by ethanol extract of abnormal Savda Munziq of traditional Uighur medicine. Evid based Complement Alternat Med. 2008; DOI: 10.1093/ecam/nen1062
• [25]Yusup A, Upur H, Umar A, Moore N: Protective effects of Munziq and Mushil of Abnormal Savda to mitochondrial oxidative damage. Fundam Clin Pharmacol 2004, 18:471-6.
• [26]Chung WT, Lee SH, Kim JD, Sung NS, Wang BH, Lee SY, et al.: Effect of the extracts from Glycyrrhiza uralensis Fisch on the growth characteristics of human cell lines:Anti-tumor and immune activation activities. Cytotechnology 2001, 37:55-64.
• [27]Jo EH, Hong HD, Ahn NC, Jung JW, Yang SR, Park JS, et al.: Modulations of the Bcl-2/Bax family were involved in the chemopreventive effects of licorice root (Glycyrrhiza uralensis Fisch) in MCF-7 human breast cancer cell. J Agric Food Chem 2004, 52:1715-9.
• [28]Allahverdiyev A, Duran N, Cetiner S, Ozguven M: Investigation of the anticancerogenic effect of the essential oil of Melissa officinalis L. Pharma Pharmacol Lett 2001, 11:26-9.
• [29]Canadanovi-Brunet J, Cetkovi G, Djilas S, Tumbas V, Bogdanovi G, Mandi A, et al.: Radical scavenging, antibacterial, and antiproliferative activities of Melissa officinalis L. Extracts J Med Food 2008, 11:133-43.
• [30]Huang X, Kojima-Yuasa A, Norikura T, Kennedy David O, Hasuma T, Matsui-Yuasa I: Mechanism of the anti-cancer activity of Zizyphus jujuba in HepG2 cells. Am J Chin Med 2007, 35:517-32.
• [31]Harborne JB, Williams CA: Advances in flavonoid research since 1992. Phytochemistry 2000, 55:481-504.
• [32]Kizaibek M, Popescu R, Prinz S, Upur H, Singhuber J, Zehl M, et al. Towards modernization of the formulation of the traditional uighur medicine herbal preparation abnormal savda munziq. Evid Based Complement Alternat Med. doi:10.1155/2012/863101.
• [33]Ren W, Qiao Z, Wang H, Zhu L, Zhang L: Flavonoids: promising anticancer agents. Med Res Rev 2003, 23:519-34.
• [34]Wilson JW, Booth C, Potten CS: Apoptosis gene. Kluwer Academic Publisher, Boston, Dordrecht/London; 1998.
• [35]Liu YL, Tang LH, Liang ZQ, You BG, Yang SL: Growth inhibitory and apoptosis inducing by effects of total flavonoids from Lysimachia clethroides Duby in human chronic myeloid leukemia K562 cells. J Ethnopharmacol 2010, 131:1-9.
• [36]Earnshaw WC, Martins LM, Kaufmann SH: Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 1998, 68:383-424.
• [37]Czabotar PE, Lessene G, Strasser A, Adams JM: Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 2014, 15:49-63.
• [38]Adhami VM, Aziz MH, Mukhtar H, Ahmad N: Activation of prodeath Bcl-2 family proteins and mitochondrial apoptosis pathway by sanguinarine in immortalized human HaCaT keratinocytes. Clin Cancer Res 2003, 9:3176-82.
• [39]Bold RJ, Chandra J, McConkey DJ: Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content. Ann Surg Oncol 1999, 6:279-85.
• [40]Davis JM, Navolanic PM, Weinstein-Oppenheimer CR, Steelman LS, Hu W, Konopleva M, et al.: Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance. Clin Cancer Res 2003, 9:1161-117.
• [41]Chiu CP, Harley CB: Replicative senescence and cell immortality: the role of telomeres and telomerase. Proc Soc Exper Biol Med 1997, 214:99-106.
• [42]Shay J, Wright WE: Telomerase therapeutics for cancer; challenge and the new directions. Nat Rev Drug Discover 2006, 5:577-84.
• [43]Kondo S, Tanaka Y, Kondo Y, Hitomi M, Barnett GH, Ishizaka Y, et al.: Antisense telomerase treatment: induction of two distinct pathways, apoptosis and differentiation. FASEB J 1998, 12:801-11.
• [44]Hahn WC, Meyerson M: Telomerase activation, cellular immortalization and cancer. Ann Med 2000, 33:123-9.
• [45]Boklan J, Nanjangud G, Mackenzie KL, May C, Sadelain M, Moore MA: Limited proliferation and telomere dysfunction following telomerase inhibition in immortal murine fibriblasts. Cancer Res 2002, 62:2104-14.
• [46]Jaio MU, Wei XL: Telomere and telomerase in oncology. Cell Res 2002, 12:1-7.
• [47]Mandal M, Kumar R: Bcl-2 modulates telomerase activity. J Biol Chem 1997, 272(22):14183-7.
• [48]Ishii H, Mimori K, Vecchione A, Sutheesophon K, Fujiwara T, Mori M, et al.: Effect of exogenous E2F-1 on the expression of common chromosome fragile site genes. FHIT and WWOX Biochem Biophys ResCommun 2004, 316:1088-93.
• [49]Mady HH, Melhem MF: FHIT protein expression and its relation to apoptosis, tumor histologic grade and prognosis in colorectal adenocarcinoma: an immunohistochemical and image analysis study. Clin Exper Metastasis 2002, 19:351-8.
• [50]Sevignani C, Calin GA, Cesari R, Sarti M, Ishii H, Yendamuri S, et al.: Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in breast cancer cell lines. Cancer Res 2003, 63:1183-7.
• [51]Roz L, Gramegna M, Ishii H, Croce CM, Sozzi G: Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines. Proc Nat Acad Sci USA 2002, 99:3615-20.
• [52]Ckim H, Yoo JS, Lee CT, Kim YW, Han SK, Shim YS, et al.: FHIT protein enhances paclitaxel-induced apoptosis in lung cancer cells. Int J Cancer 2006, 118:1692-8.
• [53]Ceballos-Cancino G, Espinosa M, Maldonado V, Melendez-Zajgla J: Regulation of mitochondrial Smac/DIABLO-selective release by surviving. Oncogene 2007, 26:7569-75.
• [54]Altieri DC: The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 2001, 7:542-7.
• [55]Lanham S, Herber AT, Watt P: HPV detection and measurement of HPV-16, telomerase and survivin transcripts in colposcopy clinic patients. J Clin Pathol 2001, 54:304-8.